# Clinical Trials Data EGFR - Document 110

# A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

## Clinical Trial: https://clinicaltrials.gov/study/NCT01994057

"eligibilityCriteria": "Inclusion Criteria:\n\nThe main patient entry criteria included: age\u2265 18 years ; histologically and cytologically proved NSCLC; Eastern cooperative oncology group performance status (ECOG PS)\u22642; adequate hematological , renal, and hepatic functions. Exclusion Criteria:\n\nuncontrolled systemic disease ,any evidence of clinically active interstitial lung diseases, and other chemotherapy at the time of inclusion. The protocol was approved by the Ethical Committee of Cancer Center of Sun Yat-Sen University (CCSU), and written informed consent was obtained form each patient.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "locally advanced or metastatic NSCLC (non-small cell lung cancer) patients; administrated with gefitinib,erlotinib .",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial is for NSCLC patients treated with gefitinib or erlotinib. These drugs are typically used for patients \*with\* EGFR mutations. While the eligibility criteria doesn't explicitly mention EGFR mutation status as a requirement, the use of these targeted therapies strongly suggests that patients with EGFR mutations are the intended population. Therefore, a patient with an EGFR mutation would likely be \*\*eligible\*\*, provided they also meet the other inclusion criteria (age, performance status, organ function) and don't have any of the exclusion criteria (uncontrolled systemic disease, interstitial lung disease, concurrent chemotherapy).